The European Society of Cardiology (ESC) Congress 2026, set to begin on August 28, 2026, in Munich, Germany, will collect some of the biggest trials and most impactful news in cardiology over the last 12 months. From heart failure and stroke to cardiomyopathy and lipid-lowering, every headlining disease state will be addressed during this 3-day conference. Major potential treatments like aficamten and pacibekitug will prove their potential, while data from terminated trials like LIBREXIA ACS and CARDIO-TTRansform will provide valuable insights into future treatment strategies for underrepresented populations.
